Konstanze Richter - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Konstanze Richter's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Konstanze Richter
Verified
Journalist, Juve Patent
Cologne
Beats
politics investmentsEconomics business
Physics, astrophysics and the law.
Content
By Konstanze Richter Verified| Juve Patent@ The dispute centred on Novartis’ patent EP 2 501 384, which protects a method of treating proliferative disorders and other pathological conditions mediated by BCR-ABL, C-KIT, DDR1, DDR2 or PDGF-R kinase activity. In simpler terms, it protects the administration of nilotinib together with apple sauce. Nilotinib is an anti-cancer medication used to treat chronic myelogenous leukaemia (CML). Novartis is also researching its use in treating Alzheimer’s disease.
By Konstanze Richter Verified| Juve Patent@ The proceedings between Yellow Sphere and Knaus Tabbert related to EP 3 356 109 B1. They centred on the interpretation of product-by-process claims. EP 109 covers a new type of frame for campervans that is particularly light yet strong. Erwin Härtwich and Alexander Christ are listed as inventors in the EPO register. The former was plaintiff alongside Yellow Sphere. Yellow Sphere is a Cologne-based company that specialises in the development, registration and marketing of intellectual property rights.
By Konstanze Richter Verified| Juve Patent@ The dispute centred on Novartis’ patent EP 2 501 384, which protects a method of treating proliferative disorders and other pathological conditions mediated by BCR-ABL, C-KIT, DDR1, DDR2 or PDGF-R kinase activity. In simpler terms, it protects the administration of nilotinib together with apple sauce. Nilotinib is an anti-cancer medication used to treat chronic myelogenous leukaemia (CML). Novartis is also researching its use in treating Alzheimer’s disease.
Company Info
Juve Patent
Cologne, North Rhine-Westphalia, Germany
+49 221 9138800